ASND vs BNTX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ASND · Ascendis Pharma A/S$256.82 ▲ 1.33%
BNTX · BioNTech$87.51 ▲ 1.92%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ASND +31.0%
- BNTX -16.7%
Head to head
| Metric | ASND | BNTX |
|---|---|---|
| Price | $256.82 | $87.51 |
| Change today | ▲ 1.33% | ▲ 1.92% |
| Market cap | $16.90B | $21.70B |
| Return, 3 months | +0.5% | -5.7% |
| Return, year to date | +20.4% | -8.1% |
| Return, 1 year | +23.3% | -15.2% |
| P/E (TTM) | 20.5 | – |
| P/B | 10.5 | 1.1 |
| P/E percentile vs own 5y | 94th | 41st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +114.7% | -59.5% |
| Net profit growth (YoY) | +632.7% | -112.3% |
| Gross margin | 91.3% | 75.5% |
| Operating margin | 25.1% | -46.4% |
| Net margin | 70.8% | -63.6% |
| Return on equity | 118.8% | -9.3% |
| Analyst target vs. price | +21.0% | +42.7% |
| Analyst buy share | 94% | 79% |
| RSI (14) | 65 | 43 |
| 30-day volatility | 22.4% | 39.7% |
| Max drawdown, 1 year | -19.7% | -29.7% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BNTX is the largest of the group by market value.
- ASND has returned the most over the past year.
- ASND is growing revenue fastest.
- ASND keeps the most profit per dollar of sales.
- ASND has been the calmest stock over the last 30 days.